{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T22:32:26Z","timestamp":1774477946641,"version":"3.50.1"},"reference-count":131,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100230"],"award-info":[{"award-number":["82100230"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["KLICD-2022-Z2"],"award-info":[{"award-number":["KLICD-2022-Z2"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["WK9110000168"],"award-info":[{"award-number":["WK9110000168"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2020T130112ZX"],"award-info":[{"award-number":["2020T130112ZX"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2020130"],"award-info":[{"award-number":["2020130"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research Fund for the Key Laboratory of Anhui Province","award":["82100230"],"award-info":[{"award-number":["82100230"]}]},{"name":"Research Fund for the Key Laboratory of Anhui Province","award":["KLICD-2022-Z2"],"award-info":[{"award-number":["KLICD-2022-Z2"]}]},{"name":"Research Fund for the Key Laboratory of Anhui Province","award":["WK9110000168"],"award-info":[{"award-number":["WK9110000168"]}]},{"name":"Research Fund for the Key Laboratory of Anhui Province","award":["2020T130112ZX"],"award-info":[{"award-number":["2020T130112ZX"]}]},{"name":"Research Fund for the Key Laboratory of Anhui Province","award":["2020130"],"award-info":[{"award-number":["2020130"]}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["82100230"],"award-info":[{"award-number":["82100230"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["KLICD-2022-Z2"],"award-info":[{"award-number":["KLICD-2022-Z2"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["WK9110000168"],"award-info":[{"award-number":["WK9110000168"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2020T130112ZX"],"award-info":[{"award-number":["2020T130112ZX"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2020130"],"award-info":[{"award-number":["2020130"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["82100230"],"award-info":[{"award-number":["82100230"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["KLICD-2022-Z2"],"award-info":[{"award-number":["KLICD-2022-Z2"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["WK9110000168"],"award-info":[{"award-number":["WK9110000168"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2020T130112ZX"],"award-info":[{"award-number":["2020T130112ZX"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2020130"],"award-info":[{"award-number":["2020130"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Postdoctoral Foundation of Hefei","award":["82100230"],"award-info":[{"award-number":["82100230"]}]},{"name":"Postdoctoral Foundation of Hefei","award":["KLICD-2022-Z2"],"award-info":[{"award-number":["KLICD-2022-Z2"]}]},{"name":"Postdoctoral Foundation of Hefei","award":["WK9110000168"],"award-info":[{"award-number":["WK9110000168"]}]},{"name":"Postdoctoral Foundation of Hefei","award":["2020T130112ZX"],"award-info":[{"award-number":["2020T130112ZX"]}]},{"name":"Postdoctoral Foundation of Hefei","award":["2020130"],"award-info":[{"award-number":["2020130"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Hepatitis B virus (HBV) is a hepatotropic virus with the potential to cause chronic infection, and it is one of the common causes of liver disease worldwide. Chronic HBV infection leads to liver cirrhosis and, ultimately, hepatocellular carcinoma (HCC). The persistence of covalently closed circular DNA (cccDNA) and the impaired immune response in patients with chronic hepatitis B (CHB) has been studied over the past few decades. Despite advances in the etiology of HBV and the development of potent virus-suppressing regimens, a cure for HBV has not been found. Both the innate and adaptive branches of immunity contribute to viral eradication. However, immune exhaustion and evasion have been demonstrated during CHB infection, although our understanding of the mechanism is still evolving. Recently, the successful use of an antiviral drug for hepatitis C has greatly encouraged the search for a cure for hepatitis B, which likely requires an approach focused on improving the antiviral immune response. In this review, we discuss our current knowledge of the immunopathogenic mechanisms and immunobiology of HBV infection. In addition, we touch upon why the existing therapeutic approaches may not achieve the goal of a functional cure. We also propose how combinations of new drugs, and especially novel immunotherapies, contribute to HBV clearance.<\/jats:p>","DOI":"10.3390\/pathogens11101116","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T22:53:19Z","timestamp":1664405599000},"page":"1116","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Advances in Immunotherapy for Hepatitis B"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1720-1135","authenticated-orcid":false,"given":"Dongyao","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China"},{"name":"Blood and Cell Therapy Institute, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China"},{"name":"Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medicine and Medical Center, University of Science and Technology of China, Hefei 230001, China"},{"name":"Anhui Provincial Key Laboratory of Blood Research and Applications, Hefei 230001, China"},{"name":"Anhui Province Key Laboratory of Immunology in Chronic Diseases, Bengbu Medical College, Bengbu 233030, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binqing","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China"},{"name":"Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medicine and Medical Center, University of Science and Technology of China, Hefei 230001, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiming","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China"},{"name":"Blood and Cell Therapy Institute, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China"},{"name":"Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medicine and Medical Center, University of Science and Technology of China, Hefei 230001, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41467-018-02988-5","article-title":"Inhibition of overactive TGF-\u03b2 attenuates progression of heterotopic ossi-fication in mice","volume":"9","author":"Wang","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41577-021-00549-4","article-title":"Immunobiology and pathogenesis of hepatitis B virus infection","volume":"22","author":"Iannacone","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: Viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/j.jhep.2015.01.018","article-title":"Strategies to control hepatitisHepatitis B: Public policy, epidemiology, vaccine and drugs","volume":"62","author":"Locarnini","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","article-title":"Hepatitis B Virus infection","volume":"384","author":"Trepo","year":"2014","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"18035","DOI":"10.1038\/nrdp.2018.35","article-title":"Hepatitis B virus infection","volume":"4","author":"Yuen","year":"2018","journal-title":"Nat. Rev. Dis. Primers."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A global scientific strategy to cure hepatitis B","volume":"4","author":"Revill","year":"2019","journal-title":"Lancet Gastroenterolhepatol"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"11344","DOI":"10.1038\/s41598-020-68226-5","article-title":"Optimized ex vivo stimulation identifies multi-functional HBV-specific T cells in a majority of chronic hepatitis B patients","volume":"10","author":"Chua","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/hep.27406","article-title":"The global burden of liver disease: The major impact of China","volume":"60","author":"Wang","year":"2014","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41392-021-00776-0","article-title":"Restoration of HBV-specific CD8 (+) T-cell responses by sequential low-dose IL-2 treatment in non-responder patients after IFN-\u03b1 therapy","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ebiom.2019.07.058","article-title":"Hepatectomy promotes recurrence of liver cancer by enhancing IL-11-STAT3 signaling","volume":"46","author":"Wang","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e01463-20","DOI":"10.1128\/AAC.01463-20","article-title":"Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731","volume":"64","author":"Huang","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity","volume":"30","author":"Ott","year":"2012","journal-title":"Vaccine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"J21","DOI":"10.1016\/j.vaccine.2013.08.012","article-title":"Reprint of: Epidemiological serosurvey of Hepatitis B in China--declining HBV prevalence due to Hepatitis B vaccination","volume":"31","author":"Liang","year":"2013","journal-title":"Vaccine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S1473-3099(15)00218-2","article-title":"Seroepidemiology of hepatitis B virus infection in 2 million men aged 21\u201349 years in rural China: A population-based, cross-sectional study","volume":"16","author":"Liu","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3201\/eid2305.161477","article-title":"Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China","volume":"23","author":"Cui","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"104816","DOI":"10.1016\/j.antiviral.2020.104816","article-title":"Mechanisms of HBV immune evasion","volume":"179","author":"Kuipery","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/hep.20408","article-title":"Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers","volume":"40","author":"Fontaine","year":"2004","journal-title":"Hepatology"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Lee, H.W., Lee, J.S., and Ahn, S.H. (2020). Hepatitis B Virus Cure: Targets and Future Therapies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010213"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: Towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1086\/599332","article-title":"Evaluation of the impact of hepatitis B vaccination among children born during 1992\u20132005 in China","volume":"200","author":"Liang","year":"2009","journal-title":"J. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Velkov, S., Ott, J.J., Protzer, U., and Michler, T. (2018). The Global Hepatitis B Virus Genotype Distribution Approximated from Available Gen-otyping Data. Genes, 9.","DOI":"10.3390\/genes9100495"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/s41586-022-04857-0","article-title":"Structural insights into the HBV receptor and bile acid transporter NTCP","volume":"606","author":"Park","year":"2022","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/s41586-022-04845-4","article-title":"Structure of the bile acid transporter and HBV re-ceptor NTCP","volume":"606","author":"Asami","year":"2022","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","article-title":"Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes","volume":"146","author":"Ni","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1136\/gut.44.5.759","article-title":"Mechanisms of immune escape in viral hepatitis","volume":"44","author":"Rosenberg","year":"1999","journal-title":"Gut"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41467-020-20316-8","article-title":"Hepatitis B virus rigs the cellular metabolome to avoid innate immune recog-nition","volume":"12","author":"Zhou","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1053\/jhep.2003.50208","article-title":"Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: Analysis and review of the literature","volume":"37","author":"Mondou","year":"2003","journal-title":"Hepatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e60747","DOI":"10.7554\/eLife.60747","article-title":"Application of human liver organoids as a pa-tient-derived primary model for HBV infection and related hepatocellular carcinoma","volume":"10","author":"Crignis","year":"2021","journal-title":"Elife"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev.pathol.1.110304.100230","article-title":"Immunobiology and pathogenesis of viral hepatitis","volume":"1","author":"Guidotti","year":"2006","journal-title":"Annu. Rev. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"104812","DOI":"10.1016\/j.antiviral.2020.104812","article-title":"Current knowledge on Hepatitis Delta Virus replication","volume":"179","author":"Lucifora","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"104925","DOI":"10.1016\/j.antiviral.2020.104925","article-title":"Hepatitis B virus biology and life cycle","volume":"182","author":"Tsukuda","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.tim.2018.01.009","article-title":"Hepatitis B Virus","volume":"26","author":"Shih","year":"2018","journal-title":"Trends Microbiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jhep.2016.02.008","article-title":"Intracellular transport and egress of hepatitis B virus","volume":"64","author":"Blondot","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s00018-019-03021-8","article-title":"Orthologous CRISPR\/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus","volume":"76","author":"Kostyushev","year":"2019","journal-title":"Cell Mol. Life Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41564-020-0678-0","article-title":"Core components of DNA lagging strand synthesis machinery are essential for hepatitis B virus cccDNA for-mation","volume":"5","author":"Wei","year":"2020","journal-title":"Nat. Microbiol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Wei, L., and Ploss, A. (2021). Mechanism of Hepatitis B Virus cccDNA Formation. Viruses, 13.","DOI":"10.3390\/v13081463"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.immuni.2021.05.005","article-title":"Identification of a Kupffer cell subset ca-pable of reverting the T cell dysfunction induced by hepatocellular priming","volume":"54","author":"Andreata","year":"2021","journal-title":"Immunity"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/hep.23043","article-title":"Hepatic regulatory T cells and Kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver","volume":"50","author":"Breous","year":"2009","journal-title":"Hepatology"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Ortega-Prieto, A.M., and Dorner, M. (2017). Immune Evasion Strategies during Chronic Hepatitis B and C Virus Infection. Vaccines, 5.","DOI":"10.3390\/vaccines5030024"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/cmi.12339","article-title":"IFITM3-containing exosome as a novel mediator for anti-viral response in dengue virus infection","volume":"17","author":"Zhu","year":"2015","journal-title":"Cell Microbiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/ni.2647","article-title":"Exosomes mediate the cell-to-cell transmission of IFN-\u03b1-induced antiviral activity","volume":"14","author":"Li","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.chom.2012.08.010","article-title":"Short-range exosomal transfer of viral RNA from infected cells to plasmacytoid dendritic cells triggers innate immunity","volume":"12","author":"Dreux","year":"2012","journal-title":"Cell Host Microbe."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.4049\/jimmunol.1301459","article-title":"IPS-1 is essential for type III IFN production by hepato-cytes and dendritic cells in response to hepatitis C virus infection","volume":"192","author":"Okamoto","year":"2014","journal-title":"J. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.coi.2016.09.005","article-title":"T cell exhaustion and immune-mediated disease-the potential for therapeutic exhaustion","volume":"43","author":"McKinney","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Vincent, I.E., Zannetti, C., Lucifora, J., Norder, H., Protzer, U., Hainaut, P., Zoulim, F., Tommasino, M., Trepo, C., and Hasan, U. (2011). Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0026315"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.coviro.2021.04.003","article-title":"Innate immunity and HBV persistence","volume":"49","author":"Chiale","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.jhep.2016.01.026","article-title":"Adaptive immunity in HBV infection","volume":"64","author":"Bertoletti","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jcyt.2017.07.011","article-title":"T-cell therapy for chronic viral hepatitis","volume":"19","author":"Bertoletti","year":"2017","journal-title":"Cytotherapy"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"497","DOI":"10.5009\/gnl17233","article-title":"Immunotherapy for Chronic Hepatitis B Virus Infection","volume":"12","author":"Bertoletti","year":"2018","journal-title":"Gut Liv."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"721975","DOI":"10.3389\/fimmu.2021.721975","article-title":"HBV-Specific CD8+ T-Cell Tolerance in the Liver","volume":"12","author":"Baudi","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","article-title":"CD8 (+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection","volume":"77","author":"Thimme","year":"2003","journal-title":"J. Virol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"591269","DOI":"10.3389\/fimmu.2020.591269","article-title":"Immunomodulation Induced During Interferon-\u03b1 Therapy Impairs the Anti-HBV Immune Response Through CD24 (+) CD38 (hi) B Cells","volume":"11","author":"Fu","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/jmcb\/mjab067","article-title":"Transcriptomic characteristics and impaired immune function of pa-tients who retest positive for SARS-CoV-2 RNA","volume":"13","author":"Wang","year":"2021","journal-title":"J. Mol. Cell Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1136\/gutjnl-2011-301073","article-title":"Innate and adaptive immune responses in chronic hepatitis B virus infections: Towards restoration of immune control of viral infection","volume":"61","author":"Bertoletti","year":"2012","journal-title":"Gut"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jhep.2015.03.020","article-title":"Characterization of novel entecavir resistance mutations","volume":"63","author":"Hayashi","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nri1573","article-title":"Immunology of hepatitis B virus and hepatitis C virus infection","volume":"5","author":"Rehermann","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12072-013-9506-4","article-title":"Balance lost: T cell immunity in progressive HBV infection","volume":"8","author":"Bengsch","year":"2014","journal-title":"Hepatol. Int."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Raziorrouh, B., Heeg, M., Kurktschiev, P., Schraut, W., Zachoval, R., Wendtner, C., Wachtler, M., Spannagl, M., Denk, G., and Ulsenheimer, A. (2014). Inhibitory phenotype of HBV-specific CD4+ T-cells is characterized by high PD-1 expression but absent coregulation of multiple inhibitory molecules. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0105703"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1172\/JCI33402","article-title":"Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection","volume":"118","author":"Lopes","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1002\/hep.23936","article-title":"The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function","volume":"52","author":"Raziorrouh","year":"2010","journal-title":"Hepatology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/hep.24249","article-title":"Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection","volume":"53","author":"Schurich","year":"2011","journal-title":"Hepatology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"S331","DOI":"10.1111\/j.1872-034X.2007.00221.x","article-title":"Immune response and tolerance during chronic hepatitis B virus infection","volume":"37","author":"Bertoletti","year":"2007","journal-title":"Hepatol. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2249.2007.03547.x","article-title":"Peripheral blood dendritic cells are phenotypically and functionally intact in chronic hepatitis B virus (HBV) infection","volume":"151","author":"Tavakoli","year":"2008","journal-title":"Clin. Exp. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41586-019-1620-6","article-title":"Dynamics and genomic landscape of CD8 (+) T cells undergoing hepatic priming","volume":"574","author":"Simone","year":"2019","journal-title":"Nature"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Sun, C., Fu, B., Gao, Y., Liao, X., Sun, R., Tian, Z., and Wei, H. (2012). TGF-\u03b21 down-regulation of NKG2D\/DAP10 and 2B4\/SAP expression on human NK cells contributes to HBV persistence. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1002594"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Wang, D., Sun, Z., Zhu, X., Zheng, X., Zhou, Y., Lu, Y., Yan, P., Wang, H., Liu, H., and Jin, J. (2022). GARP-mediated active TGF-\u03b21 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT. Blood, Epub ahead of print.","DOI":"10.1182\/blood.2022015474"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nm.3856","article-title":"Metabolic regulation of hepatitis B immunopathol-ogy by myeloid-derived suppressor cells","volume":"21","author":"Pallett","year":"2015","journal-title":"Nat. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/cei.12470","article-title":"Defective natural killer cell anti-viral capacity in paediatric HBV infection","volume":"179","author":"Heiberg","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"266","DOI":"10.5847\/wjem.j.1920-8642.2022.068","article-title":"Neutrophils inhibit CD8 (+) T cells immune response by arginase-1 sig-naling in patients with sepsis","volume":"13","author":"Dai","year":"2022","journal-title":"World J. Emerg. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0168-1702(03)00043-1","article-title":"Dominant mutations of hepatitis B virus variants in hepatoma accumulate in B-cell and T-cell epitopes of the HBx antigen","volume":"92","author":"Hwang","year":"2003","journal-title":"Virus Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1172\/JCI121957","article-title":"PD-1 blockade partially recovers dysfunctional vi-rus-specific B cells in chronic hepatitis B infection","volume":"128","author":"Salimzadeh","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1172\/JCI121960","article-title":"Circulating and intrahepatic antiviral B cells are de-fective in hepatitis B","volume":"128","author":"Burton","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_74","unstructured":"GBD 2019 Hepatitis B Collaborators (2022). Global, regional, and national burden of hepatitis B, 1990\u20132019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol. Hepatol., 7, 796\u2013829."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jhep.2017.02.026","article-title":"Targeting hepatic macrophages to treat liver diseases","volume":"66","author":"Tacke","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.4049\/jimmunol.1701801","article-title":"Elevated Hepatic CD1d Levels Coincide with Invariant NKT Cell Defects in Chronic Hepatitis B Virus Infection","volume":"200","author":"Tan","year":"2018","journal-title":"J. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/nm.2811","article-title":"Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunity","volume":"18","author":"Zeissig","year":"2012","journal-title":"Nat. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nri1309","article-title":"NKT cells: What\u2019s in a name?","volume":"4","author":"Godfrey","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.3389\/fimmu.2019.03127","article-title":"Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection","volume":"10","author":"Meng","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hep.32314","article-title":"Getting to HBV cure: The promising paths forward","volume":"76","author":"Fung","year":"2022","journal-title":"Hepatology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41577-018-0088-1","article-title":"Dendritic cell subsets in T cell programming: Location dictates function","volume":"19","author":"Eisenbarth","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"105058","DOI":"10.1016\/j.antiviral.2021.105058","article-title":"Investigation of multidrug-resistance mutations of hepatitis B virus (HBV) in a large cohort of chronic HBV-infected patients with treatment of nucleoside\/nucleotide analogs","volume":"189","author":"Liu","year":"2021","journal-title":"Antivir. Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1016\/j.cgh.2020.04.048","article-title":"Associations of HBV Genotype B vs C Infection with Relapse After Cessation of Entecavir or Tenofovir Therapy","volume":"18","author":"Chiu","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_84","first-page":"Cd003181","article-title":"Bile acids for viral hepatitis","volume":"2007","author":"Chen","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3389\/fimmu.2019.00112","article-title":"Circulating and Hepatic BDCA1+, BDCA2+, and BDCA3+ Dendritic Cells Are Differentially Subverted in Patients with Chronic HBV Infection","volume":"10","author":"Ouaguia","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"725","DOI":"10.5966\/sctm.2012-0034","article-title":"Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients","volume":"1","author":"Shi","year":"2012","journal-title":"Stem Cells Transl. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s10875-004-6249-y","article-title":"Decreased frequency and function of circulating plasmocytoid dendritic cells (pDC) in hepatitis B virus infected humans","volume":"24","author":"Duan","year":"2004","journal-title":"J. Clin. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/hep.21844","article-title":"The phenotype of hepatitis B virus-specific T cells differ in the liver and blood in chronic hepatitis B virus infection","volume":"46","author":"Chang","year":"2007","journal-title":"Hepatology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.14309\/ajg.0000000000001157","article-title":"Outcomes of Sequential Therapy with Tenofovir Alafenamide After Long-term Entecavir","volume":"116","author":"Nguyen","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00535-020-01698-4","article-title":"An expert review on the use of tenofovir ala-fenamide for the treatment of chronic hepatitis B virus infection in Asia","volume":"55","author":"Charlton","year":"2020","journal-title":"J. Gastroenterol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"m2200","DOI":"10.1136\/bmj.m2200","article-title":"Hepatitis B virus persistence and reactivation","volume":"370","author":"Shi","year":"2020","journal-title":"BMJ"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/hep.32245","article-title":"HBV covalently closed circular DNA minichromosomes in distinct epigenetic transcriptional states differ in their vulnerability to damage","volume":"75","author":"Wang","year":"2022","journal-title":"Hepatology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1172\/JCI83339","article-title":"In situ analysis of intrahepatic virological events in chronic hepatitis B virus infection","volume":"126","author":"Zhang","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1478-3231.2010.02387.x","article-title":"Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues","volume":"31","author":"Leung","year":"2011","journal-title":"Liv. Int."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S0168-8278(05)80352-6","article-title":"Comparison of anti-HBe-positive and HBe-antigen-positive chronic hepatitis B in France. French Multicentre Group","volume":"20","author":"Zarski","year":"1994","journal-title":"J. Hepatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.jhep.2020.11.043","article-title":"Viral and immune factors associated with suc-cessful treatment withdrawal in HBeAg-negative chronic hepatitis B patients","volume":"74","author":"Lens","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/liv.14155","article-title":"Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection","volume":"39","author":"Marcellin","year":"2019","journal-title":"Liv. Int."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1002\/hep.22956","article-title":"Benefits and risks of interferon therapy for hepatitis B","volume":"49","author":"Perrillo","year":"2009","journal-title":"Hepatology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1002\/hep.22920","article-title":"Benefits and risks of nucleoside analog therapy for hepatitis B","volume":"49","author":"Dienstag","year":"2009","journal-title":"Hepatology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of Tenofovir Disoproxil Fumarate and Pegin-terferon \u03b1-2a Increases Loss of Hepatitis B Surface Antigen in Patients with Chronic Hepatitis, B","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/liv.12404","article-title":"HBeAg-negative chronic hepatitis B: Why do I treat my patients with pegylated inter-feron-alfa?","volume":"34","author":"Vlachogiannakos","year":"2014","journal-title":"Liv. Int."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/eji.201141852","article-title":"Blockade of Tim-3 signaling restores the virus-specific CD8\u207a T-cell response in patients with chronic hepatitis B","volume":"42","author":"Wu","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1084\/jem.20131333","article-title":"Dysfunctional CD8+ T cells in hepa-titis B and C are characterized by a lack of antigen-specific T-bet induction","volume":"211","author":"Kurktschiev","year":"2014","journal-title":"J. Exp. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jhep.2014.07.005","article-title":"Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier pa-tients is linked to T cell differentiation","volume":"61","author":"Bengsch","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.coi.2020.04.003","article-title":"HBV as a target for CAR or TCR-T cell therapy","volume":"66","author":"Bertoletti","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/JVI.02844-06","article-title":"Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection","volume":"81","author":"Boni","year":"2007","journal-title":"J. Virol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2009.09.052","article-title":"Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B","volume":"138","author":"Fisicaro","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/S0264-410X(00)00461-8","article-title":"Immunotherapy of chronic hepatitis B by anti HBV vaccine: From present to future","volume":"19","author":"Michel","year":"2001","journal-title":"Vaccine"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"8585","DOI":"10.1016\/j.vaccine.2007.09.072","article-title":"Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: A randomized, controlled study of co-administration of HBsAg\/AS02 candidate vaccine and lamivudine","volume":"25","author":"Lau","year":"2007","journal-title":"Vaccine"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.gastro.2019.03.044","article-title":"Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients with Chronic Hepatitis","volume":"157","author":"Boni","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jhep.2017.12.007","article-title":"Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism","volume":"68","author":"Niu","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2013.02.003","article-title":"GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees","volume":"144","author":"Lanford","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1146\/annurev-virology-091919-062728","article-title":"Prospects for the Global Elimination of Hepatitis, B","volume":"8","author":"Block","year":"2021","journal-title":"Annu. Rev. Virol."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Jo, J., Tan, A.T., Ussher, J.E., Sandalova, E., Tang, X.Z., Tan-Garcia, A., To, N., Hong, M., Chia, A., and Gill, U.S. (2014). Toll-like receptor 8 agonist and bacteria trigger potent activa-tion of innate immune cells in human liver. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1004210"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"100302","DOI":"10.1016\/j.mtbio.2022.100302","article-title":"Proteomic characterization of the natural history of chronic HBV infection re-vealed by tandem mass tag-based quantitative proteomics approach","volume":"15","author":"Xun","year":"2022","journal-title":"Mater. Today Bio."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/hep.32400","article-title":"Changes in serum hepatitis B surface and e antigen, interferon-inducible protein 10, and aminotransferase levels during combination therapy of immune-tolerant chronic hepatitis B","volume":"76","author":"Perrillo","year":"2022","journal-title":"Hepatology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S2468-1253(19)30346-2","article-title":"Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: A randomised, placebo-controlled phase 1 trial","volume":"5","author":"Yuen","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e00835-18","DOI":"10.1128\/AAC.00835-18","article-title":"Novel Potent Capsid Assembly Modulators Regulate Multiple Steps of the Hepatitis B Virus Life Cycle","volume":"62","author":"Lahlali","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S2468-1253(21)00176-X","article-title":"Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: A multicentre, random-ised, placebo-controlled, phase 1 trial","volume":"6","author":"Yuen","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","article-title":"Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients with Chronic HBV Infection Na\u00efve to Nucleos(t)ide Therapy","volume":"158","author":"Bazinet","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1021\/acsinfecdis.0c00638","article-title":"HBsAg, Subviral Particles, and Their Clearance in Establishing a Functional Cure of Chronic Hepatitis B Virus Infec-tion","volume":"7","author":"Vaillant","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/21645515.2019.1651141","article-title":"Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: A phase 1b placebo-controlled trial","volume":"16","author":"Zoulim","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/cts.12791","article-title":"A Single and Multiple Ascending Dose Study of Toll-Like Receptor 7 Agonist (RO7020531) in Chinese Healthy Volunteers","volume":"13","author":"Luk","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.31255","article-title":"Toll-Like Receptor 8 Agonist GS-9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis, B","volume":"73","author":"Daffis","year":"2021","journal-title":"Hepatology"},{"key":"ref_127","first-page":"179","article-title":"Research progress of siRNA in reducing serum HBsAg levels in patients with chronic hepatitis B","volume":"28","author":"Pan","year":"2020","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Gallay, P., Ure, D., Bobardt, M., Chatterji, U., Ou, J., Trepanier, D., and Foster, R. (2019). The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0217433"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jhep.2022.05.031","article-title":"Phase IIa, randomised, double-blind study of GSK3389404 in pa-tients with chronic hepatitis B on stable nucleos(t)ide therapy","volume":"77","author":"Yuen","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/cmi.2014.124","article-title":"Chronic hepatitis B: Role of anti-platelet therapy in inflammation control","volume":"12","author":"Aiolfi","year":"2015","journal-title":"Cell Mol. Immunol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/nm1317","article-title":"Platelets mediate cytotoxic T lympho-cyte-induced liver damage","volume":"11","author":"Iannacone","year":"2005","journal-title":"Nat. Med."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/11\/10\/1116\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:41:16Z","timestamp":1760143276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/11\/10\/1116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":131,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["pathogens11101116"],"URL":"https:\/\/doi.org\/10.3390\/pathogens11101116","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,28]]}}}